-
LBA32 Principal results of the EORTC-1508 trial: A phase II randomised, multicentre study of bevacizumab vs atezolizumab and bevacizumab with acetylsalicylic acid or placebo in recurrent platinum-resistant ovarian, fallopian tube or primary peritoneal adenocarcinoma
Susana N. Banerjee, P.B. Ottevanger, Apostolos Sarivalasis, Romuald Le Scodan, Ana Montes, Judith R. Kroep, +9 more
4citations -
O-13 Efficacy and safety of ripretinib as ≥4th-line therapy for patients with gastrointestinal stromal tumor following crossover from placebo: Analyses from INVICTUS2020 Annals of Oncology conference-abstract Medicine Gastrointestinal Tumor Research and Treatment Open access
César Serrano, Michael Charles Heinrich, Suzanne George, John Raymond Zalcberg, Sebastian Bauer, Hans A. J. Gelderblom, +11 more
4citations -
475P Safety and efficacy of vimseltinib in tenosynovial giant cell tumour (TGCT): Long-term phase I update2022 Annals of Oncology article Medicine Musculoskeletal synovial abnormalities and treatments Open access cited by 12 patents
Hans A. J. Gelderblom, Albiruni Abdul Razak, Javier Martín‐Broto, Breelyn Ann Wilky, Piotr Lukasz Rutkowski, Supraja Narasimhan, +5 more
3citations -
LBA61 Early discontinuation of anti-PD-1 therapy upon achieving a complete or partial response in patients with metastatic melanoma: The multicentre prospective Safe Stop Trial
Karlijn de Joode, Evalyn E.A.P. Mulder, John B.A.G. Haanen, Karijn P.M. Suijkerbuijk, M. J. Boers‐Sonderen, H.M. Westgeest, +14 more
3citations -
1486MO The synovial and systemic pharmacokinetics and pharmacodynamics of intra-articular administration of the CSF1 receptor antibody AMB-05X in a phase II proof-of-concept trial in tenosynovial giant cell tumor2022 Annals of Oncology article Medicine Musculoskeletal synovial abnormalities and treatments Open access
Hans A. J. Gelderblom, M. Huang, Michiel A. J. van de Sande, Thomas J. Scharschmidt, O.A. Kostogryz, L. Alani, +2 more
3citations -
1629MO First-line chemotherapy (CT) in advanced well-differentiated/dedifferentiated liposarcoma (WD/DD LPS): An EORTC Soft Tissue and Bone Sarcoma Group (STBSG) retrospective analysis
Silvia Stacchiotti, W. Van der Graaf, H. Doms, Roberta G. Sanfilippo, Sandrine I. Marreaud, Winan J. van Houdt, +4 more
3citations -
1085P Health-related quality of life in stage III melanoma patients treated with neoadjuvant ipilimumab and nivolumab followed by index lymph node excision only versus therapeutic lymph node dissection: 24-week results of the PRADO trial
N.M.J. Van Den Heuvel, Irene L. M. Reijers, Judith M. Versluis, Elisa A. Rozeman, Katarzyna Jóźwiak, K.H. Blommers, +14 more
3citations -
1796P Real-world analysis of metastatic hormone-sensitive prostate cancer: Are randomized clinical trials more trustworthy? Insights from PIONEER, the European network of excellence for big data in prostate cancer
Juan Gómez Rivas, Rossella Nicoletti, Asieh Golozar, Carl Steinbeißer, Bertrand De Meulder, Robert J. Snijder, +6 more
3citations -
120P AXSANA (AXillary Surgery After NeoAdjuvant Treatment) EUBREAST-3: An international prospective multicenter cohort study to evaluate different surgical methods of axillary staging in clinically node-positive breast cancer patients treated with neoadjuvant chemotherapy (NCT04373655)2022 Annals of Oncology article Biochemistry, Genetics and Molecular Biology Breast Cancer Treatment Studies Open access
Franziska Ruf, Tarah M. Kuhn, Jana de Boniface, Oreste Gentilini, Elmar Stickeler, Isabel Teresa Rubio, +12 more
2citations -
7P An optimized Breast Cancer Index node-positive (BCIN+) prognostic model for late distant recurrence in patients with hormone receptor-positive (HR+) node-positive breast cancer2021 Annals of Oncology article Biochemistry, Genetics and Molecular Biology Breast Cancer Treatment Studies Open access
Gerrit‐Jan Liefers, Iris Noordhoek, Yi Zhang, Dennis C. Sgroi, Hein Putter, Kai Treuner, +4 more
2citations -
1995P Treatment (Tx) sequencing of tepotinib in patients (pts) with MET exon 14 (METex14) skipping non-small cell lung cancer (NSCLC): Outcomes from ≥3 years follow-up of the VISION study
Santiago Viteri, Enriqueta Felip, Egbert Frederik Smit, Rémi Veillon, Xiuning Le, J. Raskin, +12 more
2citations